Squawk Pod: Starlink-Ukraine Dispute, France Protests, and Biogenetic Rare Disease Business with BioMarin CEO

This episode of Squawk Pod, hosted by CNBC's Becky Quick, Joe Kernan, and Andrew Ross Sorkin, covers the day's business and geopolitical headlines, featuring an in-depth interview with The Economist's editor-in-chief and the CEO of BioMarin Pharmaceutical.

■ Starlink, SpaceX, and the Neocloud Shakeout
- Ukraine presidential adviser's rebuttal to Elon Musk's claims about Starlink use, Star Shield's US government control, and restored speeds
- SpaceX's $40 billion debt financing plans to buy AI chips and the structure behind the deal
- Musk's warning about "guppy-level" consolidation among AI neoclouds, with pre-market moves in CoreWeave, IonQ, and Nebius

■ Europe Protests and the Migration Debate
- The Economist editor-in-chief explains the three distinct groups behind France's demonstrations and disputes the unbridled-migration narrative
- Discussion of Europe's unsustainable welfare state, fiscal deficits, bond yields, and what the Starlink episode reveals about Europe's strategic vulnerability
- Brazil's election aftermath, with the conservative candidate refusing to concede to President Lula

■ Rare Disease Business and Flu Season
- BioMarin CEO on the FDA's new rare disease framework, the Amicus Therapeutics acquisition, debt paydown, and upcoming drug readouts
- US flu hospitalization rates running early and elevated, plus the hosts' personal vaccine experiences

The episode is well suited for viewers seeking a compact, multi-topic briefing on markets, policy, and pharmaceutical strategy. It provides context for how individual news items connect to broader industry and investment themes, and it offers starting points for those wanting to follow rare disease drug development or Europe's economic outlook further.